On June 18, 2024 BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, reported that it will participate in the hubXchange’s Immuno-Oncology Xchange – Boston 2024, taking place June 18 in Boston, Massachusetts (Press release, BostonGene, JUN 18, 2024, View Source [SID1234644436]). The event brings together executives from pharma and biotech to address and find solutions to the key issues that are currently faced in Immuno-Oncology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the event, BostonGene will lead a roundtable discussion:
Multiomic immune biomarker selection for novel IO response and toxicity assessment: tissue, blood, plasma, or all of the above?
Tuesday, June 18 | 11:20 AM ET
Speaker: Michael Goldberg, PhD, VP, Research & Development, BostonGene
This session will explore the utilization of immune biomarker strategies to enhance drug development and improve patient outcomes. The focus will be on current applications, technological advancements, novel approaches and the necessary validation and regulatory processes. By addressing these aspects, the session aims to highlight how these strategies can significantly improve therapeutic results and personalize treatment plans.
"I’m excited to participate in the hubXchange’s Immuno-Oncology Xchange and discuss how immune biomarker strategies can revolutionize drug development and patient care. By leveraging advanced technologies and comprehensive biomarker profiles, we have the potential to drastically enhance therapeutic outcomes and tailor treatments to individual patients’ needs," said Michael Goldberg, PhD, VP, Research & Development at BostonGene.